항혈소판제제를 포함한 약물상호작용에 미치는 프로톤펌프억제제의 영향: Safe 측면 = Special Review : Drug Interaction between Proton Pump Inhibitors and Clopidogrel: Safe Perspective

다국어 초록 (Multilingual Abstract)

Clopidogrel prevent atherothrombotic complications following acute coronary syndromes by inhibiting platelet aggregation.However, in case of concomitant use of clopidogrel and proton pump inhibitor (PPI) for prophylaxis of gastrointestinal (GI)bleeding, the anti-clotting of clopidogrel will be decreased because PPI inhibit competitively cytochrome P450 enzymes, especially CYP2C19. Through several pharmacodynomic studies, omeprazole, but not other PPIs, worsens surrogate markers (e.g., platelet reactivity index) of clopidogrel efficacy. And many observational studies show concomitant use of clopidogrel and PPI have increased the risks of cardiovascular (CV) events (hazard/odds ratios=1.25-1.5). However, only one prospective randomized trial (COGENT trial) of omeprazole vs. placebo in clopidogrel users show no difference in CV events (hazard ratio=1.02) and decrease the risk of GI bleeding (hazard ratio=0.13). Further well designed research will need to determine whether a pharmacodynamic effect of clopidogrel affected by PPI will be changed clinical CV events. Clinical decisions about concomitant use of PPI and clopidogrel must be balance overall risks and benefits, considering both CV and GI complications. (Korean J Med 2011;81:26-33)

참고문헌 (Reference)

1 김원희, "허혈성 심장 환자에서 프로톤펌프억제제와 Clopidogrel 병용투여 효과" 대한내과학회 80 (80): 434-442, 2011

2 Lima JP, "The potential interaction between clopidogrel and proton pump inhibitors: a systematic review" 8 : 81-, 2010

3 Lanas A, "Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase- 2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations" 55 : 1731-1738, 2006

4 Ho PM, "Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome" 301 : 937-944, 2009

5 Charlot M, "Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a Nationwide Cohort Study" 153 : 378-386, 2010

6 Laine L, "Proton pump inhibitor and clopidogrel interaction: fact or fiction" 105 : 34-41, 2010

7 O'Donoghue ML, "Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials" 374 : 989-997, 2009

8 Ray WA, "Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a Cohort Study" 152 : 337-345, 2010

9 Gilard M, "Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study" 51 : 256-260, 2008

10 Gilard M, "Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin" 4 : 2508-2509, 2006

11 Kreutz RP, "Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the Clopidogrel Medco Outcomes Study" 30 : 787-796, 2010

12 Sibbing D, "Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel" 101 : 714-719, 2009

13 Simon T, "Genetic determinants of response to clopidogrel and cardiovascular events" 360 : 363-375, 2009

14 U.S. Food and Drug Administration, "FDA reminder to avoid concomitant use of plavix (clopidoregl) and omeprazle [Internet]"

15 U.S. Food and Drug Administration, "FDA announces new warning on plavix: avoid use with Prilosec/Prilosec OTC [Internet]"

16 Yeomans N, "Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin" 103 : 2465-2473, 2008

17 Small DS, "Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel" 48 : 475-484, 2008

18 Siller-Matula JM, "Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel" 157 : 148.e1-148.e5, 2009

19 Yusuf S, "Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation" 345 : 494-502, 2001

20 Siller-Matula JM, "Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis" 8 : 2624-2641, 2010

21 Banerjee S, "Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention" 107 : 871-878, 2011

22 Connolly SJ, "Effect of clopidogrel added to aspirin in patients with atrial fibrillation" 360 : 2066-2078, 2009

23 Lanas A, "Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants" 102 : 507-515, 2007

24 Mega JL, "Cytochrome p-450 polymorphisms and response to clopidogrel" 360 : 354-362, 2009

25 Collet JP, "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a Cohort Study" 373 : 309-317, 2009

26 Li XQ, "Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities" 32 : 821-827, 2004

27 Brandt JT, "Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel" 5 : 2429-2436, 2007

28 Bhatt DL, "Clopidogrel with or without omeprazole in coronary artery disease" 363 : 1909-1917, 2010

29 Beitelshees AL, "Clopidogrel pharmacogenetics: promising steps towards patient care" 26 : 1681-1683, 2006

30 Desta Z, "Clinical significance of the cytochrome P450 2C19 genetic polymorphism" 41 : 913-958, 2002

31 van Boxel OS, "Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch Cohort Study" 105 : 2430-2436, 2010

32 Aronow HD, "Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial" 157 : 369-374, 2009

33 Abraham NS, "ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use" 105 : 2533-2549, 2010

34 Juurlink DN, "A population-based study of the drug interaction between proton pump inhibitors and clopidogrel" 180 : 713-771, 2009